Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

02.03.21	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
02.03.21	Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
17.02.21	Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease (GlobeNewswire)
16.02.21	Novartis Entresto® granted expanded indication in chronic heart failure by FDA (GlobeNewswire)
11.02.21	Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics (GlobeNewswire)
29.01.21	Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis (GlobeNewswire)
26.01.21	Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben (GlobeNewswire)
26.01.21	Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. (GlobeNewswire)
11.01.21	Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene (GlobeNewswire)
18.12.20	Novartis receives complete response letter from U.S. FDA for inclisiran (GlobeNewswire)
16.12.20	Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF (GlobeNewswire)
15.12.20	Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema (GlobeNewswire)
14.12.20	Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 (GlobeNewswire)
09.12.20	Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer (GlobeNewswire)
09.12.20	Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer (GlobeNewswire)
08.12.20	Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial (GlobeNewswire)
05.12.20	Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas (GlobeNewswire)
04.12.20	Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD (GlobeNewswire)
24.11.20	Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event (GlobeNewswire)
19.11.20	Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy (GlobeNewswire)
19.11.20	New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases (GlobeNewswire)
19.11.20	Novartis set to achieve 100% renewable electricity in its European operations (GlobeNewswire)
13.11.20	New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender (GlobeNewswire)
06.11.20	Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) (GlobeNewswire)
05.11.20	Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study (GlobeNewswire)
02.11.20	Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention (GlobeNewswire)
30.10.20	Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia (GlobeNewswire)
28.10.20	Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 (GlobeNewswire)
27.10.20	Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance. (GlobeNewswire)
27.10.20	Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben (GlobeNewswire)
26.10.20	Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G) (GlobeNewswire)
16.10.20	Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol (GlobeNewswire)
01.10.20	Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement (GlobeNewswire)
23.09.20	Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program (GlobeNewswire)
23.09.20	Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program (GlobeNewswire)
19.09.20	Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation (GlobeNewswire)
19.09.20	Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma (GlobeNewswire)
16.09.20	Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM (GlobeNewswire)
16.09.20	Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond (GlobeNewswire)
14.09.20	European Medicines Agency (EMA) approves safety label update for Novartis Beovu® (GlobeNewswire)
14.09.20	Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) (GlobeNewswire)
11.09.20	Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) (GlobeNewswire)
11.09.20	Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis (GlobeNewswire)
08.09.20	Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum (GlobeNewswire)
07.09.20	Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings (GlobeNewswire)
01.09.20	Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality (GlobeNewswire)
30.08.20	Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran (GlobeNewswire)
29.08.20	Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)
26.08.20	Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study (GlobeNewswire)
26.08.20	Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer